NASDAQ · ZYBT
Zhengye Biotechnology Holding Limited financials
$1.24−4.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $16.6M |
| Gross profit | $3.4M |
| Gross margin | 20.5% |
| Operating income | -$10.1M |
| Net income | -$10.0M |
| Net margin | −60.0% |
| Diluted EPS | $-0.21 |
| EBITDA | -$6.4M |
| Operating cash flow | $1.9M |
| Free cash flow | $1.8M |
| Diluted shares | 47.3M |
Balance sheet
| Period end | Dec 31 |
|---|---|
| Cash & equivalents | $7.2M |
| Short-term investments | $223.0K |
| Total debt | $9.4M |
| Total assets | $62.4M |
| Total liabilities | $18.5M |
| Shareholders' equity | $43.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology